SENSITIVITY OF GROSS STATE PRODUCT TO CYCLICAL AND STRUCTURAL CHANGE

The sensitivity of regional industry to business cycles has been widely documented. Responses of individual businesses and industries in a specific region or state to each phase of the business cycle has been less well analyzed and understood. Lacking in all the documentation, moreover, is reference to the impact of business cycles on interregional trade and regional interindustry structure and to the separation of these impacts from those due to business activity location and dislocation. To deal with these limitations, state-level location quotient and shift-share analyses of year-to-year changes in industry-specific contribution to gross state product are used in differentiating the varying degrees of cyclical sensitivity among industries and regions and then, in later studies, to account for these differences in parallel analyses of the structure of inter-regional trade and interindustry transactions among selected groups of states. A micro-to-macro analytical framework is offered, finally, for testing working hypotheses pertaining to the sensitivity of businesses, industries and regions to the business cycle and to structural dislocation.Community/Rural/Urban Development,

The R-Process Alliance: A Comprehensive Abundance Analysis of HD 222925, a Metal-Poor Star with an Extreme R-Process Enhancement of [Eu/H] = -0.14

We present a detailed abundance analysis of the bright (V = 9.02), metal-poor ([Fe/H] = -1.47 +/- 0.08) field red horizontal-branch star HD 222925, which was observed as part of an ongoing survey by the R-Process Alliance. We calculate stellar parameters and derive abundances for 46 elements based on 901 lines examined in a high-resolution optical spectrum obtained using the Magellan Inamori Kyocera Echelle spectrograph. We detect 28 elements with 38 <= Z <= 90; their abundance pattern is a close match to the Solar r-process component. The distinguishing characteristic of HD 222925 is an extreme enhancement of r-process elements ([Eu/Fe] = +1.33 +/- 0.08, [Ba/Eu] = -0.78 +/- 0.10) in a moderately metal-poor star, so the abundance of r-process elements is the highest ([Eu/H] = -0.14 +/- 0.09) in any known r-process-enhanced star. The abundance ratios among lighter (Z <= 30) elements are typical for metal-poor stars, indicating that production of these elements was dominated by normal Type II supernovae, with no discernible contributions from Type Ia supernovae or asymptotic giant branch stars. The chemical and kinematic properties of HD 222925 suggest it formed in a low-mass dwarf galaxy, which was enriched by a high-yield r-process event before being disrupted by interaction with the Milky Way.Comment: Accepted for publication in the Astrophysical Journal (17 pages, 4 figures, 3 tables

Chromospheric Activity of HAT-P-11: an Unusually Active Planet-Hosting K Star

Kepler photometry of the hot Neptune host star HAT-P-11 suggests that its spot latitude distribution is comparable to the Sun's near solar maximum. We search for evidence of an activity cycle in the CaII H & K chromospheric emission $S$-index with archival Keck/HIRES spectra and observations from the echelle spectrograph on the ARC 3.5 m Telescope at APO. The chromospheric emission of HAT-P-11 is consistent with a $\gtrsim 10$ year activity cycle, which plateaued near maximum during the Kepler mission. In the cycle that we observed, the star seemed to spend more time near active maximum than minimum. We compare the $\log R^\prime_{HK}$ normalized chromospheric emission index of HAT-P-11 with other stars. HAT-P-11 has unusually strong chromospheric emission compared to planet-hosting stars of similar effective temperature and rotation period, perhaps due to tides raised by its planet.Comment: 16 pages, 8 figures; accepted to the Astrophysical Journa

Monkey Malaria in a European Traveler Returning from Malaysia

In 2007, a Finnish traveler was infected in Peninsular Malaysia with Plasmodium knowlesi, a parasite that usually causes malaria in monkeys. P. knowlesi has established itself as the fifth Plasmodium species that can cause human malaria. The disease is potentially life-threatening in humans; clinicians and laboratory personnel should become more aware of this pathogen in travelers

Minor Role of Plasminogen in Complement Activation on Cell Surfaces

Atypical hemolytic uremic syndrome (aHUS) is a rare, but severe thrombotic microangiopathy. In roughly two thirds of the patients, mutations in complement genes lead to uncontrolled activation of the complement system against self cells. Recently, aHUS patients were described with deficiency of the fibrinolytic protein plasminogen. This zymogen and its protease form plasmin have both been shown to interact with complement proteins in the fluid phase. In this work we studied the potential of plasminogen to restrict complement propagation. In hemolytic assays, plasminogen inhibited complement activation, but only when it had been exogenously activated to plasmin and when it was used at disproportionately high concentrations compared to serum. Addition of only the zymogen plasminogen into serum did not hinder complement-mediated lysis of erythrocytes. Plasminogen could not restrict deposition of complement activation products on endothelial cells either, as was shown with flow cytometry. With platelets, a very weak inhibitory effect on deposition of C3 fragments was observed, but it was considered too weak to be significant for disease pathogenesis. Thus it was concluded that plasminogen is not an important regulator of complement on self cells. Instead, addition of plasminogen was shown to clearly hinder platelet aggregation in serum. This was attributed to plasmin causing disintegration of formed platelet aggregates. We propose that reduced proteolytic activity of plasmin on structures of growing thrombi, rather than on complement activation fragments, explains the association of plasminogen deficiency with aHUS. This adds to the emerging view that factors unrelated to the complement system can also be central to aHUS pathogenesis and suggests that future research on the mechanism of the disease should expand beyond complement dysregulation.Peer reviewe

NFI plots as complementary reference data in forest inventory based on airborne laser scanning and aerial photography in Finland

201

The R-Process Alliance: Chemical Abundances for a Trio of R-Process-Enhanced Stars -- One Strong, One Moderate, One Mild

We present detailed chemical abundances of three new bright (V ~ 11), extremely metal-poor ([Fe/H] ~ -3.0), r-process-enhanced halo red giants based on high-resolution, high-S/N Magellan/MIKE spectra. We measured abundances for 20-25 neutron-capture elements in each of our stars. J1432-4125 is among the most r-process rich r-II stars, with [Eu/Fe]= +1.44+-0.11. J2005-3057 is an r-I star with [Eu/Fe] = +0.94+-0.07. J0858-0809 has [Eu/Fe] = +0.23+-0.05 and exhibits a carbon abundance corrected for evolutionary status of [C/Fe]_corr = +0.76, thus adding to the small number of known carbon-enhanced r-process stars. All three stars show remarkable agreement with the scaled solar r-process pattern for elements above Ba, consistent with enrichment of the birth gas cloud by a neutron star merger. The abundances for Sr, Y, and Zr, however, deviate from the scaled solar pattern. This indicates that more than one distinct r-process site might be responsible for the observed neutron-capture element abundance pattern. Thorium was detected in J1432-4125 and J2005-3057. Age estimates for J1432-4125 and J2005-3057 were adopted from one of two sets of initial production ratios each by assuming the stars are old. This yielded individual ages of 12+-6 Gyr and 10+-6 Gyr, respectively.Comment: 30 pages, includes a long table, 5 figure

Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting

Objectives We set out to determine the reasons for serum vedolizumab (VDZ) trough concentration (TC) measurements in inflammatory bowel disease (IBD) patients and to evaluate treatment modifications after therapeutic drug measurement (TDM). We also evaluated the effect of increased dosing on patients' response to VDZ therapy. Methods We performed a retrospective cohort study of IBD patients who received VDZ therapy at Helsinki University Hospital and whose VDZ levels were measured between June 2014 and December 2018. Results Altogether, 90 patients (32 Crohn's disease and 58 ulcerative colitis) and 141 VDZ TC measurements were included. 24.1% of measurements took place during induction and 75.9% during the maintenance phase. During induction, 64.7% reached the target TC >20 mu g/ml. During maintenance therapy, 82.2% of VDZ TCs were within or exceeded the suggested target range of 5-15 mu g/ml. Reasons for TDM were: secondary nonresponse (44.0%), assessment of adequate VDZ TC (25.5%), primary nonresponse (12.8%), adverse events (6.4%), and other (11.3%). No treatment changes occurred after 60.3% of VDZ measurements. Increased dose frequency was used after 25.5% of VDZ measurements and 33.3% of these patients experienced improvement. Altogether, 31 (34.4%) patients discontinued the therapy due to inadequate treatment response. No anti-vedolizumab antibodies were detected. Conclusions During the maintenance of VDZ therapy, the majority of VDZ TCs were within the suggested range. Measurement of VDZ TC did not lead to any treatment changes in two-thirds of patients. Dose optimization occurred in a quarter of patients and a third of them benefited from it.Peer reviewe

Fluid management in patients with acute kidney injury-A post-hoc analysis of the FINNAKI study

Purpose: Whether positive fluid balance among patients with acute kidney injury (AKI) stems from decreased urine output, overzealous fluid administration, or both is poorly characterized. Materials and methods: This was a post hoc analysis of the prospective multicenter observational Finnish Acute Kidney Injury study including 824 AKI and 1162 non-AKI critically ill patients. Results: We matched 616 AKI (diagnosed during the three first intensive care unit (ICU) days) and non-AKI patients using propensity score. During the three first ICU days, AKI patients received median [IQR] of 11.4 L [8.0-15.2]L fluids and non-AKI patients 10.2 L [7.5-13.7]L, p < 0.001 while the fluid output among AKI patients was 4.7 L [3.0-7.2]L and among non-AKI patients 5.8 L [4.1-8.0]L, p < 0.001. In AKI patients, the median [IQR] cumulative fluid balance was 2.5 L [-0.2-6.0]L compared to 0.9 L [-1.4-3.6]L among non-AKI patients, p < 0.001. Among the 824 AKI patients, smaller volumes of fluid input with a multivariable OR of 0.90 (0.88-0.93) and better fluid output (multivariable OR 1.12 (1.07-1.18)) associated with enhanced change of resolution of AKI. Conclusions: AKI patients received more fluids albeit having lower fluid output compared to matched critically ill non-AKI patients. Smaller volumes of fluid input and higher fluid output were associated with better AKI recovery. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).Peer reviewe